Form 4: Catalyst Pharmaceuticals Executive Sells Shares on Open Market
SEC Form 4 Filing
Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, sold shares of common stock on the open market for personal reasons.
Summary
- Gary Ingenito, the Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, executed transactions involving the company's common stock.
- On May 13, 2025, Ingenito exercised options to acquire 200,000 shares at $3.42 per share and sold the same amount on the open market at a weighted average price of $23.68, retaining 68,873 shares.
- On May 14, 2025, Ingenito exercised options to acquire 44,000 shares at $4.64 per share and sold the same amount on the open market at a weighted average price of $23.63, retaining 68,873 shares.
- Following these transactions, Ingenito directly owns 68,873 shares of common stock and holds options to purchase 546,282 additional shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Management Comments
- The shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies. Investors often monitor these transactions for insights into management's perspective on the company's future prospects, although personal financial planning is also a common motivation.
Comparison to Industry Standards
- Executive compensation packages often include stock options as incentives.
- The vesting schedules and exercise prices are typical for such arrangements.
- Comparing Ingenito's transactions to those of executives at similar-sized pharmaceutical companies (e.g., Acadia Pharmaceuticals, Neurocrine Biosciences) would provide a benchmark for assessing the scale and frequency of these activities.
Stakeholder Impact
- Shareholders may interpret the stock sale as a lack of confidence, although the stated reason is for personal financial planning.
- The impact on employees, customers, suppliers, and creditors is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 12/02/2020 | Options for 44,000 shares vested in three annual tranches beginning on this date. |
| 12/30/2021 | Options for 200,000 shares vested in three annual tranches beginning on this date. |
| 05/13/2025 | Ingenito exercised options for 200,000 shares at $3.42 and sold them at a weighted average price of $23.68. |
| 05/14/2025 | Ingenito exercised options for 44,000 shares at $4.64 and sold them at a weighted average price of $23.63. |
| 05/15/2025 | Date of Form 4 filing. |
| 12/02/2026 | Expiration date for options to purchase 44,000 shares. |
| 12/30/2027 | Expiration date for options to purchase 200,000 shares. |
Keywords
Catalyst Pharmaceuticals, CPRX, Gary Ingenito, insider trading, Form 4, stock sale, option exercise, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.